BidaskClub lowered shares of TG Therapeutics (NASDAQ:TGTX) from a hold rating to a sell rating in a report issued on Tuesday, April 10th.
Several other equities analysts also recently commented on TGTX. B. Riley restated a buy rating and issued a $21.50 price target on shares of TG Therapeutics in a research note on Monday, December 11th. HC Wainwright reiterated a buy rating and set a $33.00 target price on shares of TG Therapeutics in a research note on Monday, December 11th. Raymond James Financial reiterated a buy rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. Zacks Investment Research downgraded shares of TG Therapeutics from a hold rating to a sell rating in a research note on Saturday, January 13th. Finally, ValuEngine upgraded shares of TG Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. TG Therapeutics has an average rating of Buy and an average price target of $24.60.
Shares of TGTX stock traded up $0.70 during trading on Tuesday, hitting $13.85. 571,352 shares of the stock traded hands, compared to its average volume of 1,524,762. TG Therapeutics has a 52-week low of $7.25 and a 52-week high of $17.35. The firm has a market cap of $1,012.77, a PE ratio of -7.18 and a beta of 1.20.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.46). TG Therapeutics had a negative net margin of 77,945.40% and a negative return on equity of 145.58%. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. sell-side analysts forecast that TG Therapeutics will post -1.68 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Senzar Asset Management LLC lifted its position in TG Therapeutics by 56.9% in the fourth quarter. Senzar Asset Management LLC now owns 1,355,178 shares of the biopharmaceutical company’s stock valued at $11,112,000 after acquiring an additional 491,678 shares during the last quarter. University of Notre Dame DU Lac purchased a new stake in shares of TG Therapeutics in the fourth quarter valued at about $2,483,000. Goldman Sachs Group Inc. raised its holdings in shares of TG Therapeutics by 1,335.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 311,793 shares of the biopharmaceutical company’s stock valued at $2,557,000 after buying an additional 290,066 shares during the last quarter. Kennedy Capital Management Inc. raised its holdings in shares of TG Therapeutics by 39.0% in the fourth quarter. Kennedy Capital Management Inc. now owns 585,439 shares of the biopharmaceutical company’s stock valued at $4,801,000 after buying an additional 164,210 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its holdings in shares of TG Therapeutics by 176.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock valued at $2,886,000 after buying an additional 155,535 shares during the last quarter. 47.33% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers TG Therapeutics (TGTX) to Sell” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/04/17/bidaskclub-downgrades-tg-therapeutics-tgtx-to-sell.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.